StockNews.AI
SGHT
StockNews.AI
181 days

Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025

1. SGHT will release Q4 and full-year 2024 results on March 5, 2025. 2. A conference call will discuss the financial results after the market closes. 3. SGHT focuses on innovative, minimally invasive eye care technologies. 4. The company’s main products target prevalent eye diseases like glaucoma. 5. Investor access to the call will be available live and for 90 days.

5m saved
Insight
Article

FAQ

Why Bullish?

Upcoming earnings reports often lead to increased investor interest and price movements. Past companies have benefitted from positive earnings surprises.

How important is it?

Earnings results are critical for valuations and can guide investor sentiment. The products' potential impact on market competition adds significance.

Why Short Term?

Earnings reports typically affect stock prices primarily in the short-term. Historical trends show immediate price adjustments post-report.

Related Companies

NASDAQ:SGHT
February 19, 2025 16:05 ET  | Source: Sight Sciences, Inc. MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024, after the market close on Wednesday, March 5, 2025. The Company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com, on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event. About Sight SciencesSight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (“MGD”), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information. Sight Sciences, the Sight Sciences logo, TearCare, SmartHub and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories. © 2025 Sight Sciences. All rights reserved. Media contact:pr@sightsciences.com Investor contact:Philip TaylorGilmartin Group415.937.5406investor.relations@sightsciences.com

Related News